Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

David J. Kuter, MD DPhil, Michael Wajnrajch, MD MPA, Betina Hernandez, MD, Rong Wang, MPH, Raul Chertkoff, MD MBA, Ari Zimran, MD

Blood (2018) 132 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2018-99-112660

Published: 2018

Journal Articles

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz-Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt

Blood (2018) 132 (Supplement 1): 633.

https://doi.org/10.1182/blood-2018-99-118492

Published: 2018

Journal Articles

Excretion and Distribution of the 60-kDa PEG Moiety Used in BAY 94-9027 in Male Wistar Rats

Andreas Baumann, Thomas Schwarz, Frank Hucke, Isabel Piel, Steffen Sandmann

Blood (2017) 130 (Supplement 1): 3674.

https://doi.org/10.1182/blood.V130.Suppl_1.3674.3674

Published: 2017

Journal Articles

Factor IX Padua: From Biochemistry to Gene Therapy

Valder Arruda, MD PhD, Ben J. Samelson-Jones, MDPhD

Blood (2016) 128 (22): SCI-9.

https://doi.org/10.1182/blood.V128.22.SCI-9.SCI-9

Published: 2016

Journal Articles

Blood 's 70th anniversary: musings of a Blood editor, 2003-2007

Sanford J. Shattil

Blood (2016) 127 (22): 2649–2651.

https://doi.org/10.1182/blood-2015-11-635755

Published: 2016

Journal Articles

Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Saara Laukkanen, Thomas Liuksiala, Matti Nykter, Merja Heinäniemi, Olli Lohi

Blood (2015) 126 (23): 3646.

https://doi.org/10.1182/blood.V126.23.3646.3646

Published: 2015

Journal Articles

Cathepsin B Mediated Lysosomal Degradation in Macrophages Controls the Pharmacokinetics of the Therapeutic Protein Asparaginase

Laurens T Van Der Meer, PhD, Samantha YA Terry, PhD, Dorette van Ingen Schenau, MSc, Kiki Andree, MSc, Gerben M Franssen, BSc, Debbie Roeleveld, MSc, Bart Metselaar, PhD, Thomas Reinheckel, PhD, Peter M Hoogerbrugge, MD PhD, Otto C Boerman, PhD, Frank N van Leeuwen, PhD

Blood (2015) 126 (23): 3768.

https://doi.org/10.1182/blood.V126.23.3768.3768

Published: 2015

Journal Articles

Novel Approach to Study Biodistribution and Accumulation of Pegylated Recombinant Factor VIII in Haemophilia A Mice

Vu P. Hong, PhD, Ayman Ismail, PhD, Nancy Moore, Robert Peters, PhD, Joe Salas, PhD

Blood (2015) 126 (23): 3517.

https://doi.org/10.1182/blood.V126.23.3517.3517

Published: 2015

Journal Articles

Mod-5014, a Long-Acting FVIIa-CTP, Proposing a Novel Prophylactic Treatment Supporting Less Frequent Subcutaneous or Intravenous Injections with a Similar Mechanism of Action to rFVIIa: Proof-of-Concept in Hemophilic Animal Models

Lior Binder, MSc, Ahuva Bar-Ilan, PhD, Malka Hoffman, Gili Hart, PhD

Blood (2015) 126 (23): 4670.

https://doi.org/10.1182/blood.V126.23.4670.4670

Published: 2015

Journal Articles

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Peter L. Turecek, PhD, Juergen Siekmann, PhD, Artur Mitterer, PhD, Michael Graninger, PhD, Gerald Schrenk, PhD, Peter Matthiessen, PhD, Hanspeter Rottensteiner, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD

Blood (2015) 126 (23): 3536.

https://doi.org/10.1182/blood.V126.23.3536.3536

Published: 2015

Journal Articles

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Kami J. Maddocks, MD, John Pagel, MD PhD, John C. Byrd, MD, Scott Stromatt, Farrukh Awan, MD MS

Blood (2014) 124 (21): 4671.

https://doi.org/10.1182/blood.V124.21.4671.4671

Published: 2014

Journal Articles

The Therapeutic Protein Asparaginase Is Efficiently Cleared By Bone Barrow and Spleen Resident Macrophages

Laurens T van der Meer, PhD, Samantha YA Terry, PhD, Dorette S van IngenSchenau, MSc, Kiki C Andree, MSc, Peter M Hoogerbrugge, MD PhD, Otto C Boerman, PhD, Frank N van Leeuwen, PhD

Blood (2014) 124 (21): 3630.

https://doi.org/10.1182/blood.V124.21.3630.3630

Published: 2014

Journal Articles

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Tadeusz Robak, MD, Andrzej Hellman, Javier Loscertales, MD, Ewa Lech-Maranda, MD PhD, John M. Pagel, MD PhD, Anthony R. Mato, MD, John C. Byrd, MD, Farrukh Awan, MD MS, Holger Hebart, MD, Jose A Garcia-Marco, MD PhD, Brian T. Hill, MD PhD, Michael Hallek, MD, Scott Stromatt, Janusz Kloczko, Professor

Blood (2014) 124 (21): 5642.

https://doi.org/10.1182/blood.V124.21.5642.5642

Published: 2014

Journal Articles

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

John C. Byrd, John M. Pagel, Farrukh T. Awan, Andres Forero, Ian W. Flinn, Delva P. Deauna-Limayo, Stephen E. Spurgeon, Leslie A. Andritsos, Ajay K. Gopal, John P. Leonard, Amy J. Eisenfeld, Jeannette E. Bannink, Scott C. Stromatt, Richard R. Furman

Blood (2014) 123 (9): 1302–1308.

https://doi.org/10.1182/blood-2013-07-512137

Published: 2014

Journal Articles

Mod-5014, a Novel Long-Acting FVIIa Proposing An Improved Prophylactic and On Demand Treatment For Hemophilic Patients Following SC and IV Administration – Comprehensive In -Vitro and In -Vivo evaluation In Preparation For Clinical Studies

Gili Hart, PhD, Oren Hershkovitz, PhD, Ahuva Bar Iilan, Miri Zakar, Lior Binder, Eyal Fima, PhD

Blood (2013) 122 (21): 3578.

https://doi.org/10.1182/blood.V122.21.3578.3578

Published: 2013

Journal Articles

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Amy Shapiro, MD, John Pasi, MBChB, PhD, FRCP, FRCPath, Johnny Mahlangu, MD, David J. Perry, MD, PhD, FRCP, FRCPath, Jerry S Powell, MD, Margaret V. Ragni, MD, MPH, Leonard A. Valentino, MD, FAAP, Margareth Ozelo, MD, PhD, Karen Nugent, MSc, Shuanglian Li, MD, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 2350.

https://doi.org/10.1182/blood.V122.21.2350.2350

Published: 2013

Journal Articles

Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR TM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)

Tadeusz Robak, Andrzej Hellman, Janusz Kloczko, Javier Loscertales, Ewa Lech-Maranda, John M. Pagel, MD, PhD, Anthony Mato, John C. Byrd, MD, Farrukh T Awan, MD, Holger Hebart, Jose A Garcia-Marco, Brian T. Hill, MD, PhD, Michael Hallek, MD, Scott Stromatt, Ulrich Jaeger

Blood (2013) 122 (21): 2860.

https://doi.org/10.1182/blood.V122.21.2860.2860

Published: 2013

Journal Articles

Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Kami Maddocks, John M. Pagel, MD, PhD, Susan O'Brien, John C. Byrd, MD, Scott Stromatt, Farrukh T Awan, MD

Blood (2013) 122 (21): 4165.

https://doi.org/10.1182/blood.V122.21.4165.4165

Published: 2013

Journal Articles

UV-C Treatment Of Intermediates Of Biologicals To Inactivate Viruses Without Denaturing Desired Protein

Albrecht Groener, Christine Dreier

Blood (2013) 122 (21): 4822.

https://doi.org/10.1182/blood.V122.21.4822.4822

Published: 2013

Journal Articles

Rational Development Of Lipegfilgrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor, Using Glycopegylation Technology

Felix Mahlert, Karsten Schmidt, Hermann Allgaier, Patrick Liu, Udo Müller, Wenyan David Shen

Blood (2013) 122 (21): 4853.

https://doi.org/10.1182/blood.V122.21.4853.4853

Published: 2013

NARROW

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Excretion and Distribution of the 60-kDa PEG Moiety Used in BAY 94-9027 in Male Wistar Rats

Factor IX Padua: From Biochemistry to Gene Therapy

Blood 's 70th anniversary: musings of a Blood editor, 2003-2007

Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Cathepsin B Mediated Lysosomal Degradation in Macrophages Controls the Pharmacokinetics of the Therapeutic Protein Asparaginase

Novel Approach to Study Biodistribution and Accumulation of Pegylated Recombinant Factor VIII in Haemophilia A Mice

Mod-5014, a Long-Acting FVIIa-CTP, Proposing a Novel Prophylactic Treatment Supporting Less Frequent Subcutaneous or Intravenous Injections with a Similar Mechanism of Action to rFVIIa: Proof-of-Concept in Hemophilic Animal Models

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

The Therapeutic Protein Asparaginase Is Efficiently Cleared By Bone Barrow and Spleen Resident Macrophages

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

Mod-5014, a Novel Long-Acting FVIIa Proposing An Improved Prophylactic and On Demand Treatment For Hemophilic Patients Following SC and IV Administration – Comprehensive In -Vitro and In -Vivo evaluation In Preparation For Clinical Studies

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR TM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

UV-C Treatment Of Intermediates Of Biologicals To Inactivate Viruses Without Denaturing Desired Protein

Rational Development Of Lipegfilgrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor, Using Glycopegylation Technology

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only